Table 3.
Incidence of Kidney Injury in Selected High‐Risk Individuals by Treatment Arm in PROVE IT‐TIMI 22
| Subgroup | Rise in sCr With Baseline sCr as Referent | Atorvastatin 80 mg QD | Pravastatin 40 mg QD | P Value |
|---|---|---|---|---|
| Diabetic patients (n=643) | ≥1.5‐fold or ≥0.3‐mg/dL rise | 11.8% | 9.6% | 0.37 |
| ≥1.5‐fold | 4.67% | 3.73% | 0.55 | |
| ≥2.0‐fold | 0.93% | 0.62% | 0.69 | |
| ≥3.0‐fold or sCr ≥4.0 mg/dL | 0.00% | 0.00% | NA | |
| Baseline eGFR <60 mL/min per 1.73 m2 (n=3104) | ≥1.5‐fold or ≥0.3‐mg/dL rise | 12.9% | 11.6% | 0.64 |
| ≥1.5‐fold | 3.42% | 1.93% | 0.29 | |
| ≥2.0‐fold | 1.14% | 0.39% | 0.62 | |
| ≥3.0‐fold or sCr ≥4.0 mg/dL | 0.00% | 0.00% | NA |
eGFR indicates estimated glomerular filtration rate; NA, not applicable; PROVE IT‐TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22; sCr, serum creatinine.